presentation_pavelpetrycki_v4
TRANSCRIPT
C o n t a c t : P a v e l P e t r y c k i
a r t z o n e@symp a t i c o . c a
4 1 6 . 9 4 9 . 4 6 2 6 c e l l
F e b r u a r y 2 , 2 0 1 5
work samplesbeer • cars • drugs and everything in between
Pavel Petrycki
GET† 5 BONUS SONGS,
FROM OVER 3 MILLION.Inside Specially Marked 24-Can Packs.
ETET†† O S SO GOBONUS SONGONUS SONG5 BBO
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music. All downloads are for promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
GET† 5 BONUS SONGS,
FROM OVER 3 MILLION.Inside Specially Marked 24-Can Packs.
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music. All downloads are for promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music. All downloads are for promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
GET† 5 BONUS SONGS,
FROM OVER 3 MILLION.Inside Specially Marked 24-Can Packs.
ANEW NIGHTIS HERE.
®/MD Anheuser-Busch, Inc.
AHTGNI
T
HISWNE
ERE HHTGNI
E.T
A
NEWNIGHT IS HERE.
®/MD Anheuser-Busch, Inc.
®/MD Anheuser-Busch, Inc.
ERE
E H IS
T HGWE
ERE
IG NNE
E H IS
A
WE
A
NE
A
®/MD Anheuser-Busch, Inc.
NEW NIGHTIS HERE.
A
A
A
A
N
NE
E
WE
W
W
N
N
NI
GI
G
GH
H
TH
T
N
NE
E
WE
W
W
N
N
NI
GI
G
GH
H
TH
T
N
NE
E
WE
W
W
N
N
NI
GI
G
GH
H
TH
T
I N
S NE
S E
S WE
HW
HW
HN
EN
ENI
EGI
RG
RGH
RH
ETH
ET
I
S
S
S
H
H
H
E
E
E
R
R
R
E
E
I
S
S
S
H
H
H
E
E
E
R
R
R
E
E
I
S
S
S
H
H
H
E
E
E
R
R
R
E
E
I
S
S
S
H
H
H
E
E
E
R
R
R
E
E
.
.
Labatt Brands at Grip Limited
THE BRAND
1
1
1
PROGRAM OVERVIEW
HOW IT WORKS
PATIO DOMINATION
ARE YOU IN?
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
†Must be legal drinking age. Limited time offer. W
GET† A BUD LIGHT LIME T-SHIRT WITH THE PURCHASE OF A BUD LIGHT & BUD LIGHT LIME 12-CAN MIXER PACK.
*TM/MC Anheuser-Busch, Inc.
A SUBTLE TWIST OF LIME AND MINT.
Labatt Brands at Grip Limited
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Acura at Grip Limited
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Acura at Grip Limited
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
1 1
The all-new 2012 CR-V is almost here.
The 2012 is coming.
75512A028E
Model shown with accessories.
T he a -n all ew 2 2012 2 CR V is - R s alm mos st he e. er028E5512A7
“…unparalleled breadth of talent and goodness.”
For the 26th time in 30 years, the safety, quality and reliability of Honda’s Accord has made it one of Car and Driver’s 10Best.
- Car and Driver, January 2012
honda.ca
2011
2006
2001
1994
1987
20102009
2004
1999
1990
1985
2005
2000
1991
1986
2008
2003
1998
1989
1984
2007
2002
1995
1988
1983
2012
4:45 PM
Honda at Grip Limited
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Accessories may not be available on all trim levels.
See honda.ca for a complete list of accessories.© 2012 Honda Canada Inc., 180 Honda Boulevard, Markham, Ontario, Canada L6C 0H9Specifications are based on information available at the time of printing and are subject to change without notice. See a sales associate for details.Printed in Canada. 03/12 75512A025E
CR-Z122-hp, 1.5-litre, 16-valve, SOHC, i-VTEC® 4-cylinder with Integrated Motor Assist IMA® • Close-ratio 6-speed manual transmission (MT) • Available continuously variable transmission (CVT) • 4-wheel Anti-lock Braking System (ABS) with Electronic Brake Distribution (EBD) and Brake Assist • 16" aluminum-alloy wheels • 360-watt AM/FM/CD Premium audio system with MP3/Windows Media® Audio playback capability and7 speakers including subwoofer • Automatic climate control with air-filtration system • Body-coloured door handles • Body-coloured heated folding power side mirrors with integrated turn indicators • Creep-aid system (CVT only) • Drive-by-Wire Throttle System™ • Driver’s and front passenger’s illuminated vanity mirrors • Dual-stage, dual-threshold front airbags (SRS) • Electric power-assisted rack-and-pinion steering (EPS) • Folding cargo tray behind front seats • Front side airbags with passenger-side Occupant Position Detection System (OPDS) • HandsFreeLink™-bilingual Bluetooth® wireless mobile phone interface • High-Intensity Discharge (HID) headlights • Hill Start Assist (MT only) • MacPherson strut front suspension • MP3/auxiliary input jack • Power-assisted, ventilated front disc brakes • Power windows with auto-up/down driver’s window • Programmable automatic power door locks • Steering wheel-mounted audio controls • Steering wheel-mounted cruise control • Three-mode drive system (Sport, Normal, Econ) • Tilt and telescoping steering column • Variable intermittent windshield wipers • Vehicle Stability Assist (VSA®) with Traction Control
PREMIUM PACKAGEAdds to or replaces CR-Z features:Heated front seats • Honda Satellite-Linked Navigation System™ with bilingual Voice Recognition and steering wheel-mounted controls • Leather-trimmed seats
Accessories17" alloy wheels • All-season floor mats • Ashtray – cupholder style • Auto-dimming day/night rearview mirror with compass • Body side mouldings • Car cover • Cargo mat • Cargo tray • Door edge film • Door sill trim • Door sill trim – illuminated • Driver’s armrest with storage compartment • Engine block heater • Front lip spoiler • Full nose mask • Rear bumper appliqué • Rear diffuser • Side accent spoiler • Splash guards • Tailgate spoiler • Wheel locks • Wheel locks – unexposed
CR-Z20
12
1 1 2:33 PM
Crosstour
Yeah, it does that.
2012
02
201
does ah eYYe
.s thath, it
2012
Yeah, it does that.
THE OFFICIAL VEHICLE OF THE TORONTO BLUE JAYS™
1 1
20
210
E J
™SYAAYE J
ah eYYe h it does
ah eYYe s thath, it
. t
Honda at Grip Limited
13 12
2.68
warfarin Pradax 150 mg BID
1.38
Effi cacyDemonstrated signifi cantly superior effi cacy in BOTH ischemic and hemorrhagic stroke vs. warfarin, in the RE-LY trial with >18,000 AF patients1
*A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arms) or adjusted doses of warfarin (unblinded arm).
Effi cacy: PrPRADAX®150 mg BID vs. warfarin
Bleeding is the most relevant side effect of PRADAX; bleeding of any type or severity occurred in long-term treatment in 16.5% of patients with atrial fi brillation treated for the prevention of stroke and systemic embolism. As with all anticoagulants, PRADAX should be used with caution in circumstances associated with an increased risk of bleeding. Bleeding can occur at any site during therapy with PRADAX. Patients at high risk of bleeding should not be prescribed PRADAX. Close clinical surveillance (looking for signs of bleeding or anemia) is recommended throughout the treatment period, especially if risk factors are combined. Should severe bleeding occur, treatment with PRADAX must be discontinued and the source of bleeding investigated promptly. Patients who develop acute renal failure must discontinue PRADAX. Renal function test should be performed before initiation of therapy and when suspected that the renal function could decline, to exclude patients with severe renal impairment. The measurement of dabigatran-related anticoagulation may be helpful to avoid excessive high exposure to dabigatran in the presence of additional risk factors.1
Safety profi lePradax demonstrated lower risk of intracranial bleeding† in AF vs warfarin1*§
Annual Rate of Intracranial Bleeding (%)
* Adapted from Pradax Product Monograph. A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of warfarin (unblinded arm).
§Intracranial bleeding: dabigatran 150 mg BID (n=6076, no. of events=38) vs. warfarin (n=6022, no. of events=90).
†Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid, and/or subdural bleeding.
0.8
0.3
p<0.0001
Stroke or Systemic Embolism1*
No. of Events Annual Rate (%)
Warfarinn=6022 202 1.7
Pradaxn=6076 134 1.1
35%p=0.0001
Ischemic Stroke1*
No. of Events Annual Rate (%)
Warfarinn=6022 134 1.1
Pradaxn=6076 103 0.9
25%p=0.03
Hemorrhagic Stroke1*
No. of Events Annual Rate (%)
Warfarinn=6022 45 0.4
Pradaxn=6076 12 0.1
74%p<0.001
Approximately 80% of all strokes are ischemic5
12-13 0 2:11 PM
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
PRADAX (dabigatran etexilate) est indiqué pour la prévention de l’AVC et de l’embolie systémique chez les patients atteints de fi brillation auriculaire pouvant recevoir une anticoagulothérapie.
PRADAX est contre-indiqué chez les patients atteints de ce qui suit : insuffi sance rénale grave (ClCr < 30 mL/min); manifestations hémorragiques, diathèse hémorragique ou patients présentant une altération spontanée ou pharmacologique de l’hémostase; lésions associées à un risque de saignement signifi catif sur le plan clinique, telles qu’un infarctus cérébral étendu (hémorragique ou ischémique) au cours des 6 derniers mois, ulcère gastrique en évolution avec saignement récent; traitement concomitant par inhibiteurs puissants de la P-glycoprotéine tels que le kétoconazole administré par voie orale et hypersensibilité connue au dabigatran, au dabigatran etexilate ou à tout autre ingrédient contenu dans la préparation du produit ou composant du contenant.
Le saignement est l’effet secondaire le plus important de PRADAX; un saignement de toute nature ou gravité a été observé chez 16,5 % des patients souffrant de fi brillation auriculaire ayant reçu un traitement de longue durée visant à prévenir l’AVC et l’embolie systémique. Comme c’est le cas avec tous les anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans l’organisme durant le traitement par PRADAX. PRADAX ne devrait pas être prescrit aux patients à risque élevé de saignement. Une surveillance clinique étroite (visant à détecter tout signe de saignement ou d’anémie) est recommandée durant la période de traitement, surtout en présence de facteurs de risque. En cas de saignement grave, le traitement par PRADAX doit être interrompu et la source du saignement rapidement recherchée. Les patients qui présentent une insuffi sance rénale aiguë pendant le traitement par PRADAX devraient cesser de prendre ce médicament. La fonction rénale devrait être évaluée avant l’instauration du traitement et si l’on soupçonne que la fonction rénale pourrait se détériorer afi n d’exclure les patients atteints d’insuffi sance rénale grave.
L’innocuité et l’effi cacité de PRADAX n’ont pas été évaluées chez des patients présentant des valvules cardiaques mécaniques ou ceux atteints de rhumatisme cardiaque signifi catif sur le plan hémodynamique, dont une sténose mitrale. Par conséquent, l’administration de PRADAX n’est pas recommandée.
Les agents pouvant augmenter le risque d’hémorragie ne devraient pas être administrés en association avec PRADAX ou, si nécessaires, devraient être administrés avec précaution durant le traitement par PRADAX. L’administration concomitante de dronédarone augmente l’exposition à PRADAX et n’est pas recommandée. Le risque de saignement pourrait être plus élevé chez les patients qui reçoivent un traitement concomitant par inhibiteur sélectif du recaptage de la sérotonine (ISRS). Chez les patients souffrant de fi brillation auriculaire et recevant un traitement visant à prévenir l’AVC et l’embolie systémique, l’administration concomitante d’antiplaquettaires par voie orale (comme l’AAS et le clopidogrel) et d’AINS augmente le risque de saignement d’environ deux fois. L’administration concomitante de PRADAX et de l’inducteur puissant de la P-gp rifampicine diminue les concentrations plasmatiques de dabigatran et, par conséquent, devrait être évitée. Veuillez consulter la monographie du produit pour obtenir des renseignements additionnels sur les traitements qui augmentent le risque d’hémorragie.
Prière de consulter la monographie du produit pour l’information sur l’ajustement posologique chez certaines populations particulières.
Les manifestations indésirables les plus courantes observées chez 1 % des patients ayant reçu PRADAX à 150 mg bid et à 110 mg bid comprenaient : anémie (1,6 %, 1,2 %), épistaxis (1,1 %, 1,1 %), hémorragie gastro-intestinale (4,6 %, 3,3 %), hémorragie uro-génitale (1,4 %, 1,1 %), douleur abdominale (2,2 %, 2,3 %), diarrhée (1,2 %, 1,3 %), dyspepsie (3,9 %, 4,2 %) et nausée (1,2 %, 1,0 %), respectivement. Des réactions indésirables gastro-intestinales sont survenues plus fréquemment avec le dabigatran etexilate qu’avec la warfarine, et avaient trait à la dyspepsie (incluant douleur abdominale supérieure, douleur abdominale, malaise abdominal, malaise épigastrique) ou à des symptômes de pseudo-gastrite (incluant refl ux gastro-œsophagien, œsophagite, gastrite érosive, hémorragie gastrique, gastrite hémorragique, gastrite érosive hémorragique et ulcère gastro-intestinal). Une hémorragie gastro-intestinale est survenue plus fréquemment avec le traitement par PRADAX à 150 mg bid et à 110 mg bid (4,6 % et 3,3 %, respectivement) comparativement au traitement par warfarine (2,6 %). Le mécanisme sous-jacent expliquant le taux plus élevé d’hémorragies gastro-intestinales avec PRADAX n’a pas été établi.
Des réactions allergiques ou une hypersensibilité médicamenteuse, y compris l’urticaire, un bronchospasme, une éruption cutanée et un prurit, ont été rapportées par des patients ayant reçu du dabigatran etexilate. De rares cas de réactions anaphylactiques ont également été rapportés.
Pour obtenir le guide thérapeutique complet, prière de consulter la monographie du produit.
Chez les patients atteints de fi brillation auriculaire, Pradax a démontré :
Comme c’est le cas avec tous les anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans l’organisme durant le traitement par PRADAX. En cas de saignement grave, le traitement par PRADAX doit être interrompu et la source du saignement rapidement recherchée.
Les patients présentant un risque plus élevé de saignement devraient faire l’objet de surveillance clinique étroite. Un test de la coagulation, tel que le test du temps de céphaline activée peut être utile pour identifi er les patients qui présentent un risque plus élevé de saignement dû à une exposition excessive au dabigatran. *Étude de non-infériorité à répartition aléatoire menée auprès de 18 113 patients atteints de FA prédisposés à l’AVC. Les patients recevaient soit le dabigatran à 110 mg bid ou à 150 mg bid (groupe à l’insu) ou des doses ajustées de warfarine (groupe ouvert). †AVC ou embolie systémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 134) par rapport à la warfarine (n = 6 022, nombre d’événements = 202).¥AVC ischémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 103) par rapport à la warfarine (n = 6 022, nombre d’événements = 134). ‡L’hémorragie intracrânienne comprend les AVC hémorragiques attestés et les hémorragies sous-arachnoïdiennes et/ou sous-durales. §Hémorragie intracrânienne : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 38) par rapport à la warfarine (n = 6 022, nombre d’événements = 90). ¢L’hémorragie menaçant la vie était une sous-catégorie de l’hémorragie majeure et incluait : hémorragie mortelle, hémorragie intracrânienne symptomatique, hémorragie avec baisse du taux d’hémoglobine d’au moins 50 g par litre ou hémorragie nécessitant la transfusion d’au moins 4 unités de sang ou d’agents inotropes ou nécessitant une chirurgie. £Hémorragie majeure menaçant la vie : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 179) par rapport à la warfarine (n = 6 022, nombre d’événements = 218).
BIPRA111328F Visitez Pradax.ca
PrPRADAX® à 150 mg bid Indiqué pour la prévention de l’accident vasculaire cérébral (AVC) et de l’embolie systémique chez les patients atteints de fi brillation auriculaire (FA) pouvant recevoir une anticoagulothérapie1.
Est-ce que Pradax à 150 mg bid est une option thérapeutique pour ces patients atteints de FA? Patients à risque élevé
Pour toute question au sujet de Pradax, composez le 1-855-PRADAX5 (772-3295).
PATIENTS ATTEINTS DE FA PRADAX À VOSPRESCRIVEZ
PRÉDISPOSÉS À L’AVC
Réduction du risque d’AVC ou d’embolie systémique de 35 %
par rapport à la warfarine1*†
Dabigatran à 150 mg bid (1,1 %/an) par rapport à la warfarine (1,7 %/an), p=0,0001.
Réduction du risque d’AVC ischémique de 25 % par rapport à la warfarine1*¥
Dabigatran à 150 mg bid (0,9 %/an) par rapport à la warfarine (1,1 %/an), p=0,03.
Risque d’hémorragie intracrânienne‡ moins élevé de 59 %
par rapport à la warfarine1*§
Dabigatran à 150 mg bid (0,3 %/an) par rapport à la warfarine (0,8 %/an), p<0,0001.
Risque d’hémorragie menaçant la vie¢ moins élevé de 20 %
par rapport à la warfarine1*£
Dabigatran à 150 mg bid (1,5 %/an) par rapport à la warfarine (1,9 %/an), p=0,0305.
Aucune surveillance du RIN1
Références : 1. Monographie de Pradax. Boehringer Ingelheim (Canada) Ltée, 27 janvier 2012. 2. Skanes Allan C et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-136.
Pradax® est une marque déposée utilisée sous licence par Boehringer Ingelheim (Canada) Ltée.
B 1-3 2 11:51 AM
WITH PRADAXPREVENT STROKE HELP
AND SYSTEMIC EMBOLISM
See prescribing summary on page
PrPRADAX® 150 mg BID INDICATED FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN
PATIENTS WITH ATRIAL FIBRILLATION, IN WHOM ANTICOAGULATION IS APPROPRIATE.1
PrPRADAX®
carbamazepine are also expected to reduce dabigatran plasma concentrations and should be co-administered with caution.
The most common adverse reactions observed in 1% of PRADAX 150 mg BID patients and 110 mg BID patients was anemia (1.6%, 1.2%), epistaxis (1.1%, 1.1%), gastrointestinal hemorrhage (4.6%, 3.3%), urogenital hemorrhage (1.4%, 1.1%), abdominal pain (2.2%, 2.3%), diarrhea (1.2%, 1.3%), dyspepsia (3.9%, 4.2%) and nausea (1.2%, 1.0%), respectively. Gastrointestinal adverse reactions occurred more often with dabigatran etexilate than warfarin. These were related to dyspepsia (including upper abdominal pain, abdominal pain, abdominal discomfort, epigastric discomfort) or gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis and gastrointestinal ulcer). Gastrointestinal hemorrhage occurred at a higher frequency with PRADAX 150 mg BID and 110 mg BID (4.6%, 3.3%, respectively) compared to warfarin (2.6%). The underlying mechanism of the increased rate of GI bleeding has not been established.
Allergic reactions or drug hypersensitivity including urticaria, bronchospasm, rash and pruritus have been reported in patients who received dabigatran etexilate. Rare cases of anaphylactic reactions have also been reported.
Patients at an increased risk of bleeding should be closely monitored clinically. A coagulation test, such as aPTT may help to identify patients with an increased bleeding risk caused by excessive dabigatran exposure.
For complete prescribing information, please refer to the Product Monograph.* A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of warfarin (unblinded arm).
† Stroke or systemic embolism: dabigatran 150 mg BID (n=6076, no. of events=134) vs. warfarin (n=6022, no. of events=202).
‡ Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid, and/or subdural bleeding.
§ Intracranial bleeding: dabigatran 150 mg BID (no. of events=38) vs. warfarin (no. of events=90).
References: 1. Pradax Product Monograph. Boehringer Ingelheim (Canada) Ltd., 06/13/11. 2. Connolly SJ et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139–1151. 3. Connolly SJ et al. Newly Identifi ed Events in the RE-LY Trial. N Engl J Med. 2010;363:1875-1876 supp appendix. 4. Liste de médicaments publiée par la Régie de l’assurance maladie du Québec. April 2011.Pradax® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.
PRADAX (dabigatran etexilate) is indicated for the prevention of stroke and systemic embolism in patients with atrial fi brillation, in whom anticoagulation is appropriate.
PRADAX is contraindicated in patients with: severe renal impairment (CrCL <30 mL/min); hemorrhagic manifestations, bleeding diathesis, or patients with spontaneous or pharmacological impairment of hemostasis; lesions at risk of clinically significant bleeding, e.g. extensive cerebral infarction (hemorrhagic or ischemic) within the last 6 months, active peptic ulcer disease with recent bleeding; concomitant treatment with strong P-glycoprotein (P-gp) inhibitors, i.e. oral ketoconazole, and with known hypersensitivity to dabigatran, dabigatran etexilate or to any ingredient in the formulation or component of the container.
Bleeding is the most relevant side effect of PRADAX; bleeding of any type or severity occurred in long-term treatment in 16.5% of patients with atrial fi brillation treated for the prevention of stroke and systemic embolism. As with all anticoagulants, PRADAX should be used with caution in circumstances associated with an increased risk of bleeding. Bleeding can occur at any site during therapy with PRADAX. An unexplained fall in hemoglobin and/or hematocrit or blood pressure should lead to a search for a bleeding site. Patients at high risk of bleeding should not be prescribed PRADAX. Close clinical surveillance (looking for signs of bleeding or anemia) is recommended throughout the treatment period, especially if risk factors are combined. Should severe bleeding occur, treatment with PRADAX must be discontinued and the source of bleeding investigated promptly. Patients who develop acute renal failure must discontinue PRADAX. In patients who
are bleeding, an aPTT test may be useful to assist in determining an excess of anticoagulant activity, despite its limited sensitivity. An aPTT >80 sec at trough, i.e. when the next dose is due, is associated with a higher risk of bleeding.
Agents that may enhance the risk of hemorrhage should not be administered concomitantly with PRADAX, or, if necessary, should only be administered with caution. Treatments that should NOT be administered concomitantly with PRADAX due to increase in bleeding risk include: unfractionated heparin and heparin derivatives, low molecular weight heparins (LMWH), fondaparinux, bivalirudin, thrombolytic agents, GPIIb/IIIa receptor antagonists, ticlopidine, sulfinpyrazone and vitamin K antagonists such as warfarin. The concomitant use of PRADAX with the following treatments has not been studied and may increase the risk of bleeding: rivaroxaban, prasugrel and the strong P-gp inhibitors dronedarone, itraconazole, tacrolimus, cyclosporine, ritonavir, tipranavir, nelfinavir and saquinavir. Unfractionated heparin may be administered at doses necessary to maintain a patent central venous or arterial catheter. In patients with atrial fi brillation treated for the prevention of stroke and systemic embolism, the co-administration of oral anti-platelet (including ASA and clopidogrel) and NSAID therapies increases the risk of bleeding by about two-fold. If necessary, co-administration of low-dose ASA, i.e. 100 mg daily with PRADAX may be considered for other indications than stroke prevention in atrial fi brillation. The concomitant use of PRADAX with the strong P-gp inducer, rifampicin, reduces dabigatran plasma concentrations. Other P-gp inducers such as St. John’s Wort or
For patients with atrial fi brillation, PRADAX demonstrated:
reduced risk of stroke or systemic embolism vs. warfarin1-3*†
Dabigatran 150 mg BID (1.1%/yr) vs. warfarin (1.7%/yr), p=0.0001.
reduced risk of intracranial bleeding‡ vs. warfarin1-3*§
Dabigatran 150 mg BID (0.3%/yr) vs. warfarin (0.8%/yr), p<0.0001.
No INR monitoring or dose titration1
Covered by the
Liste de médicaments
du Québec with Exception Drug Status4
12:56 PM
Pr Pradax® for Stroke and Systemic Embolism Prevention in Atrial Fibrillation
A guide to support the use of Pradax.
1 0 2:10 PM
AVOID BRAND NAME CONFUSION
BETWEEN PrPRADAX®
AND PrPLAVIX®
The Pradax® and Plavix® names, verbally and by script, have been mistaken for one another. These mix-ups have been associated with similarities in orthographics, phonetics and strength.
To reduce the potential for name confusion errors, healthcare professionals are encouraged to include the generic name dabigatran when referring to Pradax®, or the name clopidogrel when referring to Plavix®. Spelling the name of the medication for verbal prescriptions is also suggested.
Pradax® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. Plavix® is a registered trademark used under license by Sanofi -aventis Canada Inc.
BIPRA121200E
Pradax at Grip Limited
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
GOÛT LÉGÈREMENTSUCRÉ, ENTIÈREMENT
NATUREL
100 CALORIES
NOUVEAU
UN GOÛT SUBLIME AVEC UNE NOUVELLE TOUCHE SPÉCIALE.
EN FAIT, 2 NOUVELLES TOUCHES.
VEUILLEZ CONSOMMER AVEC MODÉRATION.
BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES
DE BACARDI & COMPANY LIMITED.
BACARDI ET WILD VINES VOUS RASSEMBLENT À OSHEAGA !POUR PARTICIPER, VISITEZ : WWW.OSHEAGAPARTY.CA – TU PEUX
UN DES FORFAITS 3 JOURS POUR 4 PERSONNES D’UNE VALEUR DE 870 $.GAGNER
18 ans et plus. Aucun achat requis. Le concours débute à 00 h 01 m (HAE) le 27 mai 2012 et prendra fi n à 23 h 59 m (HAE) le 21 juillet 2012. La personne gagnante du grand prix sera choisie par tirage au sort le 23 juillet 2012. Pour obtenir les règlements complets du concours et pour y participer, visitez www.osheagaparty.ca. VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI ET LE SIGNE DE LA CHAUVE-SOURIS SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
FACEBOOK.COM/BACARDI
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Breezer Ananas 4x330 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
1 $Bacardi Breezer Ananas 100 Cal 4x330 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
Bacardi Superior & Cola 473 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
Wild Vines Framboise 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Superior 750 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
3 $Bacardi Superior 1,14 L
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
5 $Bacardi Superior 1,75 L
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Gold 750 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Breezer Spritzer 4x330 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
1 $Bacardi Breezer Orange 4x330 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
Wild Vines Fraise 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
Wild Vines Mûre 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi8 750 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Oakheart 750 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
2 $Bacardi Black 750 mL
TAXES INCLUSES
RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de
VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.
3 $Bacardi Gold 1,14 L
TAXES INCLUSES
0,75 $TAXES INCLUSES
0,75 $TAXES INCLUSES
0,75 $TAXES INCLUSES
0,75 $TAXES INCLUSES
1-2 0 10:50 AM
BUNDLE YOURSUMMER SALE
Flights Vacation Packages Hotels Cars Rail Cruises ToursHome Activities MobileDEALS
Add saving up to 40% to your travel itinerary. Save up to 40%* on your stay when you bundle your flight and hotel together. That’s enough savings to see more sites, take more tours or check out more restaurants on your summer getaway.
© 2012 Expedia, Inc. All rights reserved. Expedia, Expedia.ca, and the Airplane logos are registered trademarks, or trademarks, of Expedia, Inc. in the U.S. and/or other countries. Ticket fulfillment services provided by Tour East Holidays (Canada) Inc., 15 Kern Road, Suite 9, Toronto, Ontario M3B 1S9. TICO Registration No.: 50015827 and Tour East Holiday (Canada) Inc., 2000 Peel Street, Suite 735 Montréal, QC H3A 2W5. Quebec License No. 702246. *Discount limited to hotel portion of build-your-own (flight + hotel) bookings only (off Expedia.ca prices) purchased by July 2/12 for travel between June 5/12 and Sept 30/12. Some conditions apply. Only valid on select Bundle Your Summer Sale cities and properties. Offer subject to change or cancellation without notice. See expedia.ca for full details.
BisacodylBi d l
Tablets
Gentle, predictableovernight relief
Convenient, small and easy-to-swallow
Special coating
Suppositories
Gentle and predictable relief in less than an hour
Gentle, predictable relief with Tablets and SuppositoriesGentle, predictable relief with Tablets and Suppositories
The Dulcolax RangeNEW LOOK
SAME GREATPRODUCT
dulcolax.caDulcolax® may not be right for you, always read and follow the label.
UPC PRODUCT DESCRIPTION SIZE CASE PACK INNER PACK LIST PRICE
0 58341 01511 5 Dulcolax® Tablets, 5 mg 10 tabs 54 9 $1.860 58341 01513 9 Dulcolax® Tablets, 5 mg 30 tabs 54 9 $4.750 58341 01514 6 Dulcolax® Tablets, 5 mg 60 tabs 54 9 $8.570 58341 02001 0 Dulcolax® Tablets, 5 mg 100 tabs 144 12 $12.080 58341 01521 4 Dulcolax® Suppositories, 10 mg 3 supps 90 6 $3.330 58341 01523 8 Dulcolax® Suppositories, 10 mg 6 supps 90 6 $5.500 58341 01525 2 Dulcolax® Suppositories, 10 mg 100 supps 24 1 $56.07
5:57 PM
Certified General Accountants see more than numbers. When it comes to leadership,
we see the impact and opportunity behind those numbers. That’s because, in this
fast changing economic climate, innovative leadership is seeing how numbers impact
our business – before they do.
CGA-more.org
Rich Harvey, CGA Hockey Finance Manager Bauer Canada
. 1 1 - - 3:03 PM
Certified General Accountants see mor
we see the impact and opportunity behind those numbers. That’
fast changing economic climate, innovative leadership is seeing how numbers impact
our business – befor
General Accountants see mor
e impact and opportunity behind those numbers. That’
ging economic climate, innovative leadership is seeing how numbers impact
e they do. ess – befor
e than numbers. When it comes to leadership, e mor
ty behind those numbers. That’
innovative leadership is seeing how numbers impact
When it comes to leadership,
s because, in this ers. That’
s seeing how numbers impact
ership,
his
mpact
eCGA-mor
ge.or
We see the pressures of a global economy.
L E A D E R S H I P | E F F I C I E N C Y | P R O D U C T I V I T Y | S U S T A I N A B I L I T Y | M A N A G I N G R I S K
Certifi ed General Accountants see the implications and opportunities of today’s global economy. Whether as an employee or trusted consultant, your CGA looks beyond the balance sheet to help every player on your team fi nd effi ciencies, create opportunity and maximize value. That’s because they’ve learned that in a global economy, success isn’t a moving target, it’s a moving market. To help you hit your mark, choose someone who sees the bigger picture. Choose a CGA.
cga-more.org
1 1 3:23 PM
Other projects at Grip Limited
G
S
INNER PACK LIST PRICE
0
The World’sThe World’s
OTC LaxativeOTC L axativeNo.1
Our commitment in 2012NEWNEW National TV Campaign.
Time to stock your shelves!
NEW LOOKSAME GREAT
PRODUCT
BisacodylBisacodyl
Verac i t y Cap i t a l I n c .
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Integrated Facility Solutions, Inc.
����yyyy
���������
yyyyyyyyy
��
�� yy
yy �y
R E G I O N A L M E D I C A L R E S E A R C H
R E C H E R C H E M É D I C A L E R É G I O N A L E
furniture design architecture
professional services
healthcare
financial
technology
leisure
fashion
Pavel is responsible for designing and implementing over 40 logos for corporate, manufacturing, pharmaceutical, retail and fashion clients.
The following pages showcase select work samples ranging from logo design and corporate brochures to marketing and advertising campaigns.
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Which would you rather have, a cholesterol test or a final exam?For many, the first sign of heart disease is a heartattack. Did you know that one out of two adultCanadians is at risk of developing heart disease because they have high cholesterol? And that cardiovascular disease IS the leading cause of death in Canada?
High cholesterol is a major risk factor for heart disease but managing your cholesterol can be quite simple.
If any of these apply to you, cut this screening test out and ask your doctor about getting your cholesterol tested:
Woman 50 years or older
Man 40 years or older
Heart disease (angina, heart attack, coronary bypass, stroke,angioplasty)
Diabetes
Family history (mother, father, sister, brother or grandparent) of heart disease or high cholesterol
Two or more of the following:
• Overweight• Physically inactive• Smoker• High blood pressure
Call toll-free at 1-877-4-LOW-LDL(1-877-456-9535) or visitwww.makingtheconnection.ca and you will receive this free booklet describing the connection between cholesterol and heart disease.
The Canadian Diabetes Association has reviewed the “Making the Connection” program for its medical and scientificaccuracy. The Canadian Diabetes Association does not endorse the products of any pharmaceutical company. Sponsored by one of Canada’s research based pharmaceutical companies.
Use your Shopping Companion to
chart your low-cholesterol food
choices and recipe ingredients.
Keep this journal handy
for when you go grocery shopping.
Managing yourcholesterol
pharmaceutical
atorvastatine calciquecomprimés
EFFICACE POUR VISER JUSTE
Efficacité…Expérience…Études à l’appui, dansl’atteinte de la cible de
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
YOUR ANTIHYPERTENSIVE THERAPY SHOU LD BE AS DEPENDABLE AS THE SUNRISE
Prolonged & Sustained 24-Hour Blood Pressure Control▲ Provided similar efficacy in clinic [trough] blood pressure reduction to Norvasc* (amlodipine)1‡
▲ “…was also associated with a greater reduction in ambulatory blood pressure during the night-
time interval and during the last 4 hours of the dosing period” than Norvasc* (amlodipine)1
▲ MICARDIS® (40-80 mg) demonstrated at least similar efficacy to Vasotec® (5-20 mg)2,3ƒ
▲ Significantly more effective than Cozaar® 50 mg (losartan) in blood pressure reduction
18-24 hours post-dose4✪
Excellent Pharmacokinetic Profile▲ 24-hour half-life, longest of all AT1 receptor blockers3†§
▲ Fastest time to maximum plasma concentration3†§
▲ Trough to peak ratio 92-100% for 80 mg5,6
▲ 97% hepatic excretion3
Excellent Tolerability★
▲ Discontinuation rate due to adverse events was less with
MICARDIS® (2.8%) than with placebo (6.1%)3★
▲ Excellent drug interaction profile3#
▲ Not metabolized by cytochrome P450 isoenzymes3
Simple Dosing▲ 80 mg once-a-day starting and maintenance dose,
regardless of age, gender or renal status3
▲ No titration required3
▲ Can be taken with or without food3
FULL 24-HOUR PROTECTION, INCLUDINGTHE CRITICAL EARLY MORNING HOURS
HYPERTENSION NEVER TAKES TIME OFF...
NEITHER SHOULD YOURANTIHYPERTENSIVE
NEW
T E L M I S A R T A N 8 0 m g A T1 R E C E P T O R B L O C K E R
®
Pr
Antihypertensive protection day and night.
NEW
T E L M I S A R T A N 8 0 m g A T1 R E C E P T O R B L O C K E R
Pr
®
Co-promoted with
*TM Pfizer Products Inc., Pfizer Canada Inc., licensee. ® Trademark Merck & Co., Inc./Merck Frosst Canada Inc., licensed user. Cozaar® is a registered trademark of E.I. du Pont de Nemours and Company, Merck Frosst & Co., licensed user.
References: 1. Lacourcière Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Pressure Monitoring 1998;3(5):295-302. 2. Smith DHG, Neutel JM, Morgenstern P.Once-Daily Telmisartan Compared with Enalapril in the Treatment of Hypertension. Advances in Therapy 1998;16(4):229-240. 3. MICARDIS® Product Monograph, Boehringer Ingelheim (Canada) Ltd. August, 1999. 4. Mallion JM, Lacourcière Y.ABPM Comparison of the Antihypertensive Profiles of the Selective Angiotensin II Receptor Antagonists Telmisartan and Losartan in Patients with Mild-to-Moderate Hypertension. The Journal of Human Hypertension (In press). 5. Bakris G, et al.Clinical Efficacy and Safety Profiles of AT1 Receptor Antagonists. CVR&R 1999; February 1999:78-100. 6. Neutel JM, Smith DHG. Dose Response and Antihypertensive Efficacy of the AT1 Receptor Antagonist Telmisartan in Patients with Mild toModerate Hypertension. Advances in Therapy 1998;15(4):206-217.
MICARDIS® (telmisartan) is indicated for the treatment of mild to moderate hypertension.MICARDIS® may be used alone or in combination with thiazide diuretics.MICARDIS® should normally be used in those patients in whom treatment with diuretic or beta blocker was found ineffective or has been associated with unacceptable adverse effects. MICARDIS® can also be tried as an initial agent in those patients in whom the use of diuretics and/or beta blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects.If pregnancy is detected, MICARDIS® should be discontinued as soon as possible. In patients who are volume-depleted by diuretic therapy, dietary salt restrictions, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS®.
‡ Results from 12-week double-blind phase, 40 mg MICARDIS® (n=73) and 5 mg Norvasc* (n=78), p<0.0001Similar reduction in DBP was observed over the 24-hour mean period. Results after 12 weeks monotherapy asmeasured by 24-hour ABPM with MICARDIS® (n=73; increased to 80 and 120 mg as necessary for patientswhose DBP remained >90 mmHg) and Norvasc* (n=78; titrated to 5 mg and titrated to 10 mg for patients whoseDBP remained >90 mmHg). p<0.05. The recommended dose of MICARDIS® is 80 mg once-daily, 120 mg providedno additional mean reduction in blood pressure.
ƒ There was similar reduction in DBP at weeks 1, 4 , and 8. MICARDIS® 80 mg (n=72), Vasotec® 20 mg (n=72),p=0.03 for DBP, p=0.01 for SBP.
✪ ABPM 18-24h post-dose period comparing Cozaar® 50 mg (n=50) and MICARDIS® 40 and 80 mg (n=52) at week6 of therapy p<0.05.
† From product monographs of valsartan, losartan, irbesartan, and candesartan. ★ The most common adverse events are headache, upper respiratory tract infection and dizziness.§ Comparative clinical significance is investigational. # Digoxin levels should be monitored when initiating, adjusting, or discontinuing MICARDIS®.
No initial dosing adjustment is necessary for elderly patients or for patients with renal impairment, but greater sensitivity in some older individuals cannot be ruled out. For patients with hepatic impairment, a starting dose of40 mg is recommended.
Notes
LIPITOR *: Hitting targets.
LIPITOR is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol, LDL-C, TG andapolipoprotein B in hyperlipidemic and dyslipidemic conditions (including primary hypercholesterolemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemiaand familial hypercholesterolemia) when response to diet and other non-pharmacological measures alone has been inadequate.LIPITOR also raises HDL-cholesterol and therefore lowers the LDL-C/HDL-C and Total-C/HDL-C ratios (Fredrickson Type IIa and IIb). These changes in HDL-C with HMG-CoA reductaseinhibitors should be considered as modest when compared to those observed in LDL-C and do not play a primary role in the lowering of LDL-C/HDL-C and Total-C/HDL-C ratios.See prescribing information for complete warnings, precautions, dosing and administration.LIPITOR is contraindicated: During pregnancy and lactation; active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal;hypersensitivity to any component of this medication.Lipid levels should be monitored periodically and, if necessary, the dose of LIPITOR adjusted based on target lipid levels recommended by guidelines.Caution should be exercised in severely hypercholesterolemic patients who are also renally impaired, elderly, or are concomitantly being administered digoxin or CYP 3A4 inhibitors.Liver function tests should be performed before the initiation of treatment, and periodically thereafter. Special attention should be paid to patients who develop elevated serum transaminaselevels, and in these patients measurements should be repeated promptly and then performed more frequently.The effects of atorvastatin-induced changes in lipoprotein levels, including reduction of serum cholesterol on cardiovascular morbidity, mortality, or total mortality have not been established.‡ A patient-year represents the total time of exposure to LIPITOR as defined by the sum of each patient time on LIPITOR.5
¥ The Atorvastatin Versus Revascularization Treatments (AVERT) study examined the effect of intensive lipid-lowering in patients with stable coronary artery disease and LDL-C at least 3.0mmol/L in patients referred for percutaneous transluminal coronary angioplasty (PTCA). Patients were randomized for 18 months to LIPITOR 80 mg daily or to PTCA with usual medicalcare which could include lipid metabolism regulators. The results of the AVERT study should be considered as exploratory since several limitations may affect its design and conduct. Inthe medical-treated group with LIPITOR there was a trend for a reduced incidence of ischemic events and a delayed time to first ischemic event. The results also suggest that intensivetreatment to target LDL-C levels with LIPITOR is additive and complementary to angioplasty and would benefit patients referred for this procedure.1
39-60%1†
LDL -C TG
25-56%(type IV)1†
29-44%TC/HDL-C
(type IIa and IIb)1†
Clinicalresearchprogram4
EFFICACY ➣ † A powerful demonstrated effect across key lipid parameters1
EXPERIENCE ➣ More than 40 million patient-years of experience2‡
EVIDENCE ➣ Demonstrated delayed time to first ischemicevent in stable CAD patients (n=164, p=0.03)3¥
LIPITOR has a leading edge clinical research program exploringnew areas that may extend beyond lipid control4
Aiming beyond.Aiming beyond.
pharmaceutical
Because the early morning hours are critical...
Full 24-Hour Protection from BP Surges,Including the Critical Early Morning Hours
Because the early morning hours are critical...
Full 24-Hour Protection from BP Surges,Including the Critical Early Morning Hours
JSAI
Training marketers to be marketects
JEFFREY SIMBROW ASSOCIATES INC.
JSAI
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
JSAI Introduction
Jeffrey Simbrow Associates Inc. (JSAI) offers a curriculum of interactive skill-basedseminars designed to enhance the competencies of marketing executives to become moreeffective brand builders. Our training seminars, utilizing best practices, are provided inmarketing and brand planning, positioning and communication strategy development,advertising development, research, promotion and media planning.
JSAI’s internationally acclaimed training seminars have been executed for companies aroundthe world for industries as diverse as brewing, pharmaceutical, financial services,entertainment, professional sports, food and packaged goods. Our clients include leading
companies such as Interbrew, Pepsi QuakerTropicana Gatorade Canada, Pfizer, Schering, EliLilly, Corus Entertainment, Alliance Atlantis, TorontoBlue Jays, Toronto Dominion Bank… To date, wehave conducted more than 100 programs throughoutthe world including Toronto, Montreal, New York,San Francisco, Los Angeles, London, Tokyo, Seoul,Brussels, Budapest, Amman, Singapore, Bangkok,Rome, Paris, Helsinki and other major cities. Wehave trained more than 2,500 marketing managersworldwide to become “marketects”.
Who Should Attend
JSAI training seminars provide an unparalleled idea-sharing and network opportunity fora select group of senior managers. Typical titles include Chief Marketing Officer, VicePresident Marketing, Marketing Director, Sales Director, Brand Manager, Assistant BrandManager, Sales Manager, Marketing Research Manager, Advertising Agency Consultant, etc.
3
JSAI Introduction 3
Overall Objectives 4
JSAI Strengths 5
Training Programs 6
Speaker Bio 14
Case Studies 15
Client Testimonials 16
Contact Information 18
2
13
Media Planning [Code 006]Objectives:
To become familiar with/understand the language of media
To understand the basic principles underlying the construction of a media plan inorder to:
• Challenge/suggest alternatives to agency media recommendations
• Defend/explain media choices
Contents:
Key Media Terms
Strength and Weakness of Media Classes
The Media Planning Process
• Information Required
• Media Objectives
• Media Strategies
• Media Tactics
• Media Tools – Research
• What the Media Plan Should Look Like
– Plan Evaluation Checklist
Plan Execution
• Market Dynamics Media Classes
12 JSAI
marketing training
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Prepared by Jeffrey Simbrow Associates Inc.
USA June 2002
Interbrew Promotion Training Program
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jef f rey S imbrow Assoc iates Inc.
M A R K E T I N G T R A I N I N G P R O G R A MM A R K E T I N G T R A I N I N G P R O G R A M
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jeffrey Simbrow Associates Inc.
marketing training
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
All About
The Sharp LCD TV Guide
Top consumermyths about LCD
technology
Top consumer m
yths about LCD
technology
Wide Viewing AngleThe AQUOS provides a wide viewing angle of 170 degrees, bothhorizontally andvertically, allowing youto view the screen clearlyfrom virtually anywherein a room, regardless of what angle the TV or viewer is positioned in.
Clear Reproduction of Fast Moving Video ClipsAnother benefit that Sharp ASV technology brings to LCD is Sharp’sproprietary Quick Shoot component. Quick Shoot improves the quality ofmoving scenes on liquid crystal panels by achieving exceedingly highresponse times resulting in unsurpassed picture playback and realism.
High Performance Liquid Crystal Control Sharp’s High Performance LC control technology is a key benefit of the AQUOS line-up. The liquid-crystal displays (LCDs) in use today relyon picture elements, or pixels, formed by liquid-crystal (LC) cells thatchange the polarization direction of light passing through them inresponse to an electrical voltage. As the polarization direction changes, more or less of the light is able to pass through a polarizing layer on the face of the display. Change thevoltage, and the amount of light is changed. Sharp ASV technology has ahigh level of control over individual pixels allowing for the reproductionof thicker and darker contrast enabled blacks.
Best in Class Picture QualityIt’s not enough to build a bigger panel. As the panels become larger the need for a higher resolution panel becomes even more evident. For example, the Sharp LC37G4U has a unique High-Definition LCD Panelwhich packs over 3.1 million pixels in a 37" display.Compared to a plasma TV of the same screen size, this LCD panel has 30 per cent more horizontal pixels delivering a highly precise, super-realistic picture.
All About AQUOS: The Sharp LCD TV Guide
INTRODUCTION TO AQUOS 3
Horizontal 170°
Vertical 170°
Conventional LCD Advanced Super View with Quick Shoot
technology
The Canadian Pharmaceutical Marketing Program
Learning to build strongerhealthcare brands
• Improve profitability
• Gain market advantage
• Maximize value through the entire product lifecycle
www.humber.ca/healthindustry
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
The Canadian Pharmaceutical Marketing Program
Learning to build stronger healthcare brands
4-day Professional Development Program
Developed for the industry, by the industry, the CanadianPharmaceutical Marketing Program is a unique, practicalcareer development program that approaches marketingfrom a healthcare perspective. Over the course of fourintensive full-day sessions, participants will learn bestpractices for designing and implementing a successful brandstrategy in today’s dynamic pharmaceutical marketplace.
New product managers, associate product managers, andothers involved in planning and implementing marketingstrategies will walk away with an actionable framework that can be immediately applied to:
• Improve profitability
• Gain market advantage
• Maximize value through the entire product lifecycle
• Largest 4-year nursing degree program offered exclusively at a college
• Focus on primary health care & advocacy
• Outstanding faculty with professional practice & teaching experience
• Exceptional nursing simulation & anatomy labs
• Full and part-time practical nursing diploma
humber.ca/healthsciences • 416.675.5000
Congratulations to the first graduates of the UNB-Humber Bachelor of Nursing Degree
(June 2005)
• Largest nursing program in Ontario
• D iverse full-time and part-time programs
• Academic and clinical excellence
• Outstanding faculty and teaching excellence
• Modern, high-tech facilities
humber.ca/healthsciences 416.675.5000
Diplomas • Certificates • Bachelor’s Degree in Nursing Postgraduate Programs • Continuing Education
education
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
N
Enclosed Area CoverageEnc losed Area CoverageCHANEXCOMCHANEXCOM
N owhere are coverage problems more
apparent than in enclosed areas. Anyone
who has t r ied to use a mobi le radio or
cellular phone in buildings, tunnels or
subways knows the feeling.
Futurecom’s CHANEXCOM is a system
solut ion speci f ica l ly designed to solve
e n c l o s e d - a r e a c o v e r a g e p r o b l e m s .
I t p r o v i d e s t h e n e c e s s a r y
equ ipment fo r o f f -a i r s igna l
acquisition and enclosed area
RF distribution. It assures seam-
less integration of external and
internal coverage areas.
CHANEXCOM Channel Mod-
ules (CMD) ensure that only wanted
channels are allowed into coverage
extension areas, minimizing possi-
b le i n te rmod and in te r fe rence
problems. Channel Modules are
high specification, channel-selec-
tive repeaters capable of handling
digital and analog signals.
CHANEXCOM Channel Modules
can be programmed to work on-
channel or as frequency translators.
They are typically used to process
signals off-air at a head-end site. Signals can
then be distributed within the extended cov-
erage areas by conventional coaxial cables,
or over longer distances by f iber optics.
Distributed antennas or leaky coax cable
a re used t o r ad i a te t he s i gna l s i n t he
enclosed areas.
LA3B Tri-band Line Amplifiers are used
to compensate for signal losses over long
cable runs. When equipped with an option-
al AGC board they become smart, remotely
controlled devices.
CHANEXCOM supports VHF,
UHF, and 800/900 MHz fre-
q u e n c y b a n d s a n d c a n b e
equipped for remote monitoring and
control operation. This allows all
remote device settings to be opti-
mized from one central location
and provides for alarm and fail-
safe reconfiguration functionality.
CHANEXCOM Digs In
Futurecom’s CHANEXCOM enclosed
area coverage solutions have been
proven in the most demanding envi-
r o n m e n t s , i n c l u d i n g s u b w a y
systems in Toronto, New York City
and Los Angeles, Toronto’s “Under-
ground City” and Major Shopping
Malls and Office Tower Complexes
throughout the world.
CHANEXCOM is recognized among Public
Safety Agencies as the mission critical cov-
erage extension solution.
CHANEXCOM
FIBER OPTICBACKBONE
LA3B
CHANEXCOM
FIBER OPTICBACKBONE
LA3B
LA3BLA3B
LA3B
LA3B
LA3B
LA3B
PProviding high-quality portable radio cover-
age in wide-area systems and high-density
urban environments is one of the greatest chal-
lenges facing today’s radio system designers.
Their task becomes even more demanding when
additional factors such as cost, reliability, and
shortage of spectrum become part of the equa-
tion. Life would be much easier for these
hard-pressed system designers if only high qual-
ity portable coverage could be provided from
systems designed for mobile grade coverage.
F u t u r e c o m ’s M O B E X C O M Ve h i c u l a r
Repeater System (VRS) is one solution that can
solve some of the system designers’ portable
coverage problems.
M O B E X C O M p r o -
vides portable grade
coverage in systems
designed for mobile
c o v e r a g e . W h e n
mounted in a vehicle
and integrated with the system mobile i t
extends system coverage for personnel oper-
ating with portables.
MOBEXCOM can be seen as a Trunking
Gateway between a trunking and a conven-
tional system. The Trunking Gateway operates
like a trunking radio on the system side and
as a conventional radio on the local portable
side. It receives group and private calls and
retransmits them to the portable radio. The
portable radio calls are converted into the
group calls and retransmitted to the system.
The Gateway can be configured for in-band
or cross-band applications. The in-band con-
figuration is particularly beneficial as the same
portable radio can be used for communica-
tions directly with the system or via the VRS.
Loca l Area CoverageLoca l Area CoverageMOBEXCOMMOBEXCOM
Going from system to local coverage requires
only a change of channel. The Trunking Gate-
way is fully integrated with the trunking radio
and controlled by the mobile control head. It
also supports all important trunking system fea-
tures such as “go ahead” tones, group/private
calls and portable emergency transmissions.
The Trunking Gateway in a mobile appli-
cation provides portable radio coverage in
systems designed for mobile coverage. In a
fixed application it provides a cost effective
in-building coverage extension, requiring only
a single-channel distribution system that is far
less costly to implement than a multi-channel
design. As the Trunk-
ing Gateway operates
o n a d i f f e r e n t f r e -
q u e n c y f r o m t h e
system channels, high
system gains of up to
1 6 0 d B c a n b e
achieved without risking system lockup due to
the insufficient antenna isolation or high noise
floor problems that can be experienced with
BDA based solutions. In addition, it offers high
sensitivity and output power that makes the dis-
tribution system implementation very easy.
MOBEXCOM is compatible with major
t runking systems inc luding SMARTNET™
and EDACS™.
MOBEXCOM on the Move
Futurecom’s MOBEXCOM Vehicular Repeater
Systems are used by major police, ambulance
and fire agencies across North America. Their
robust construction and high specification make
them the only solution for these demanding
and lifesaving public safety applications.
WW ide-area systems provide RF coverage
across cities, provinces, states or countries.
Reliable wide-area coverage has a number
of obvious benefits:
• For Private Mobile Radio networkoperators it means higher system loading, which translates into higher air-time revenue.
• For public-safety radio systems such as police, ambulance or fire, it meansimproved safety, for both the public and service personnel.
• For utility companies, it meansmore efficient operations andlower operating costs.
The obvious way to improve
wide-area coverage is
to expand the system
infrastructure. How-
ever, there are two
fundamental drawbacks to
this approach: high cost and
limited spectrum availability.
Futurecom Systems Group Inc. pro-
vides an economical and efficient way to
deal with difficult coverage situations.
Our MULTEXCOM site extenders, in VHF, UHF,
800 and 900 MHz frequency bands, pro-
vide a reliable and cost-effective RF coverage
extension for remote communities, highways
or hilly terrain.
Futurecom MULTEXCOM site extenders
allow backbone coverage to be increased
wi thout spending mi l l ions of dol lars on
expanding network infrastructures. MULTEX-
COM site extenders are fully transparent,
system and protocol independent, and can
be used in analog or digital systems for voice
or data.
SaskTel Selects MULTEXCOM 800
SaskTel Mobility, a division of SaskTel, a
crown corporation owned by the Province of
Saskatchewan, chose Futurecom
MULTEXCOM 8 0 0 t o s o l v e a
unique challenge of providing
instant and reliable radio com-
munications to a small population
spread across a vast
prairie province.
Simply expanding
t h e m a i n n e t w o r k
infrastructure would have
been prohibitively expensive,
requiring additional site equip-
ment, as wel l as the expansion of
multi-site switches and backhaul facilities.
SaskTel chose to base i ts F leetNet
8 0 0 o n E r i c s s o n ’ s E D A C S® t r u n k e d
system. Today FleetNet 800 is the largest
private radio network in the world, providing
radio coverage over 400,000 sq. km. Fleet-
N e t 8 0 0 o p e r a t e s w i t h m o r e t h a n
160 RF s i tes , a lmost ha l f o f wh ich are
Futurecom MULTEXCOM 800 sites.
Wide Area CoverageWide Area CoverageMULTEXCOMMULTEXCOM
SITEXCOM – Frequency Translating Repeater SITEXCOM Technical Highlights
Any site can be used as a donor. As shown in the diagram, the SITEXCOM receives downlink frequency F2 from the donor
site and translates it to frequency F4. Terminals receive frequency F4 and respond on F3. The SITEXCOM receives uplink
frequency F3 and translates it to F1. As a result the donor site sees its terminals operating on F1/F2. The SITEXCOM site
is transparent to both the donor and the network. Terminals see the SITEXCOM site as just another base station which they
can freely roam to. Thanks to its high sensitivity and high output power the SITEXCOM can dramatically increase the
donor’s coverage area.
SITEXCOM Applications
Boosting revenue and cutting costs is a universal recipe for improving profitability. In the case of wireless
network operators, boosting revenue comes from increasing the number of subscribers and enlarging the access area.
Cutting costs means doing it inexpensively. Multiplying the number of base stations may be prohibitively expensive and
ineffective in many low density areas.
Frequency Translating Repeater (SITEXCOM) is the network operator’s dream-come-true. It extends RF
coverage at a much lower cost than base stations and is ideal for large, low congestion areas, coverage gaps (valleys,
cliffs etc.), highways, buildings, and underground.
SITEXCOM
COVERAGE GAPS
SITEXCOM
WIDE AREACOVERAGE
SITEXCOM
IN BUILDINGCOVERAGE
T1 T1 T1
SITEXCOM
HIGHWAY COVERAGE
DONOR
DONOR
DONORDONOR
LOCAL SWITCH
DONOR
DONOR
Highly modular construction
Easy “rear door” installation and access
Stainless steel padlockable latches
Channel Selective• Extends only desired channels. • Does not create simulcast effects. • Does not extend
competition’s channels. • Does not create or propagate
intermod products.
High Sensitivity/High Power• Provides good coverage.
Protocol Transparent• All the donor’s present and future
site features are available in theextended coverage area.
Wireless Interface• Does not require any network
expansion or telephone line connections.
Frequency Translating• Does not create simulcast effects
on the donor’s channel. • Can realize high system gain
(up to 163 dB).
On Channel (option)• Uses the same channel as
a donor site. • Ideal for applications where
simulcast is not a problem (e.g. in buildings, underground etc.).
Factory Calibrated. • Easy “no equipment” setup • Only a laptop is needed
to setup a site.
Software Controlled• Easy to reconfigure in the field.
Energy Efficient• No fans needed. • Efficient battery backup.• Low hydro bills.
Highly Modular• Easy to service and maintain.
Wireless Modem Interface (option)• Full remote alarm reporting.• Full remote programming.• Full remote monitoring.
Double Door Cabinet• Easy two stage installation.
Small Size, Weatherized Enclosure• Pole or roof installable. • Low site acquisition cost.
F1
F2
F1
F2
F3
F4
F3
F4
RF coverage by design1-800-701-9180
broad-band amplifiers vehicular repeaters channel-selectiverepeaters
technology
Ve
rac
ity
Ca
pit
al
Inc
.
Factors Favouring an Investment in the Partnership
Strong Performance
• Year-to date (as of October 15, 2003), the Partnership has gained17.7% net of all fees and expenses. On a trailing twelve-month basis,the Partnership has gained approximately 16.8% net of all fees andexpenses. These gains were achieved with considerably lower volatilitythan the overall equity markets.
Experienced Management
• Both Murray McDonald and Gregory Misztela, Managing Directors of the General Partner, have considerable senior level experience inmanaging alternative strategy equity pools and in investment research,as well as over 30 years of combined experience in the financialservices industry. Mr.McDonald has managed hedge funds forapproximately ten years and generated average annual returns in excess of 16%.
3
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2 416.777.6749 • 416.777.6784 Fax
Verac i t y Cap i ta l I nc .
K. Murray McDonaldManaging Director
Scotia Plaza40 King St. W., Suite 4900Toronto, ON M5H 4A2416.777.6749 416.777.6784 Fax
Verac i t y Cap i ta l I nc .
Verac i t y Cap i ta l Inc .
Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2
Ve
rac
ity
Ca
pit
al
Inc
.
Key Terms of the Offering cont’d
Performance Fee
The General Partner is entitled to an annual performance fee equal to20% of any increase in the net asset value of the units during eachcalendar year.
Distribution of Income
Distributions may be made at the discretion of the General Partner.
Fiscal Year End
December 31 each year
Redemptions
Commencing June 30, 2003, provided the Limited Partner has held hisor her units for at least one year, units may be redeemed once a year on thirty (30) days’ prior written notice. Limited partners may requestredemption at other times, but acceptance of such request is in thediscretion of the General Partner.
8
Veracity Capital Partners Limited Partnership (An Ontario Limited Partnership)
Minimum Subscription:$150,000($50,000 for accredited investors)
416.864.6477 416.864.6485 Fax 1.866.269.7773 Toll Free
26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2
w w w . m g i s e c u r i t i e s . c o m
Joe Sample VP Marketing & Research
416.864.6477 x222 [email protected]
26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2 866.269.7773 Toll Free 416.864.6485 Fax
SECURITIES (USA) INC.
MEMBER OF THE JOVIAN GROUP OF COMPANIES
26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2
Junior Oil & Gas Sector
Brian Kristjansen,Analyst [email protected] 403-705-4969
Jeff Sears,CFA, Associate [email protected]
July 07, 2005
financial
work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l
miscellanies